MX2012002369A - Formas de anhidrato de un derivado de piridina. - Google Patents

Formas de anhidrato de un derivado de piridina.

Info

Publication number
MX2012002369A
MX2012002369A MX2012002369A MX2012002369A MX2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A
Authority
MX
Mexico
Prior art keywords
pyridine derivative
anhydrate forms
anhydrate
forms
therapy
Prior art date
Application number
MX2012002369A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Simon Craig
Salima Zarah Ismail
Ronnie Maxwell Lawrence
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2012002369A publication Critical patent/MX2012002369A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2012002369A 2009-08-27 2010-08-25 Formas de anhidrato de un derivado de piridina. MX2012002369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
MX2012002369A true MX2012002369A (es) 2012-03-29

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002369A MX2012002369A (es) 2009-08-27 2010-08-25 Formas de anhidrato de un derivado de piridina.

Country Status (17)

Country Link
US (1) US8796269B2 (enExample)
EP (1) EP2470545B1 (enExample)
JP (3) JP2013503134A (enExample)
KR (1) KR20120056258A (enExample)
CN (1) CN102639536B (enExample)
AU (1) AU2010288502B2 (enExample)
CA (1) CA2772168C (enExample)
DK (1) DK2470545T3 (enExample)
EA (1) EA021411B1 (enExample)
ES (1) ES2440938T3 (enExample)
IL (1) IL217922A (enExample)
IN (1) IN2012DN01292A (enExample)
MX (1) MX2012002369A (enExample)
PL (1) PL2470545T3 (enExample)
SG (1) SG178231A1 (enExample)
WO (1) WO2011023733A1 (enExample)
ZA (1) ZA201200812B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010288502B2 (en) * 2009-08-27 2013-12-12 KaNDy Therapeutics Ltd. Anhydrate forms of a pyridine derivative
EP3915560A1 (en) * 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
HUE047732T2 (hu) 2015-05-18 2020-05-28 Nerre Therapeutics Ltd NK-1/NK-3 receptor antagonista vértolulások kezeléséhez
US11028099B2 (en) * 2016-12-15 2021-06-08 Glaxosmithkline Intellectual Property Development Limited NRF2 activators
PL3765024T3 (pl) 2018-03-14 2024-08-05 KaNDy Therapeutics Limited <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div>
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
JP7673064B2 (ja) 2019-11-15 2025-05-08 カンディー セラピューティクス リミテッド Nt-814の重要な中間体である6-クロロ-4-(4-フルオロ-2-メチルフェニル)ピリジン-3-アミンを作製するための新規な化学的方法
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
TW202604529A (zh) * 2024-06-18 2026-02-01 瑞士商拜耳保健消費品股份有限公司 用於製造依林奈坦(elinzanetant)前驅物之改良方法
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
PL378404A1 (pl) * 2003-01-31 2006-04-03 F. Hoffmann-La Roche Ag Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu
HRP20070471T3 (hr) * 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
US7683056B2 (en) * 2005-09-09 2010-03-23 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders
KR20100101051A (ko) * 2007-12-11 2010-09-16 씨아이피엘에이 엘티디. 조피클론 결정성 다형체, 이들의 제조 공정 및 이들의 약제 조성물
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
AU2010288502B2 (en) * 2009-08-27 2013-12-12 KaNDy Therapeutics Ltd. Anhydrate forms of a pyridine derivative
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
EA201270302A1 (ru) 2012-07-30
EP2470545B1 (en) 2013-10-09
PL2470545T3 (pl) 2014-03-31
JP6404186B2 (ja) 2018-10-10
CA2772168A1 (en) 2011-03-03
JP2017193564A (ja) 2017-10-26
US8796269B2 (en) 2014-08-05
AU2010288502B2 (en) 2013-12-12
SG178231A1 (en) 2012-03-29
US20120157450A1 (en) 2012-06-21
WO2011023733A1 (en) 2011-03-03
JP2016000739A (ja) 2016-01-07
DK2470545T3 (da) 2014-01-13
IL217922A (en) 2016-06-30
ES2440938T3 (es) 2014-01-31
EA021411B1 (ru) 2015-06-30
IL217922A0 (en) 2012-03-29
EP2470545A1 (en) 2012-07-04
KR20120056258A (ko) 2012-06-01
ZA201200812B (en) 2013-03-27
JP2013503134A (ja) 2013-01-31
CA2772168C (en) 2019-01-08
IN2012DN01292A (enExample) 2015-06-05
CN102639536A (zh) 2012-08-15
CN102639536B (zh) 2015-03-18
AU2010288502A1 (en) 2012-02-23
BR112012003435A2 (pt) 2016-02-23

Similar Documents

Publication Publication Date Title
IN2012DN01292A (enExample)
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
PH12013500473A1 (en) Triazine-oxadiazoles
MX2012000414A (es) Derivados piridin-4-ilo.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA108926C2 (ru) LibreOffice? [2,3-D] +&#34; +&#34; !+
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
MX2012013274A (es) Novedosos derivados de la pirimidina.
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
IN2012DN03182A (enExample)
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
IN2014CN04530A (enExample)
MX2013010898A (es) Novedoso derivados de la pirimidina.
TN2015000022A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
PH12015500376B1 (en) Novel bicyclic pyridinones
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IN2012DN02139A (enExample)
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
TW200833335A (en) New pyridine analogues
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
TW200833333A (en) New pyridine analogues
MY150428A (en) Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NERRE THERAPEUTICS LIMITED

FG Grant or registration